1.	A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100077, 10-C-0077, NCT01100944
2.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
3.	Preoperative Treatment of Patients With High Risk Thymoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: VHS07.0006a, NCT00387868
4.	Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDKO-125a-007, NCT01301391
5.	A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: THOR0003, SU-01142011-7369, NCT01364727
6.	Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120118, 12-C-0118, NCT01621568
7.	Nonmyeloablative Allogeneic Transplant Phase: No phase specified Type: Treatment Status: Active Age: 18 to 72 Sponsor: Other Protocol IDs: SCC-01-499, NCT01272817